CR20210486A - Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico - Google Patents

Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico

Info

Publication number
CR20210486A
CR20210486A CR20210486A CR20210486A CR20210486A CR 20210486 A CR20210486 A CR 20210486A CR 20210486 A CR20210486 A CR 20210486A CR 20210486 A CR20210486 A CR 20210486A CR 20210486 A CR20210486 A CR 20210486A
Authority
CR
Costa Rica
Prior art keywords
compounds
pharmaceutical use
pyridone compounds
tricyclic
bridge
Prior art date
Application number
CR20210486A
Other languages
English (en)
Inventor
Hong Yang
Michael L Mitchell
Devleena M Shivakumar
Jennifer R Zhang
Jiayao Li
Gregg M Schwarzwalder
Scott D Schroeder
Lan Jiang
Nathan D Shapiro
Hyung-Jung Pyun
Hongyan Guo
Buenrostro Ana Z Gonzalez
Xiaochun Han
Hang Chu
Qiaoyin Wu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70293100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20210486(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CR20210486A publication Critical patent/CR20210486A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen compuestos para usar en el tratamiento o prevención de la infección por el virus de la inmunodeficiencia humana (VIH). Los compuestos tienen la siguiente fórmula (I): incluyendo estereoisómeros y sales farmacéuticamente aceptables del mismo, en la que R1, R2, L, W1, W2, X, Y y Z son como se define en el presente documento. También se describen métodos asociados con la preparación y uso de tales compuestos, así como composiciones farmacéuticas que comprenden tales compuestos.
CR20210486A 2019-03-22 2020-03-20 Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico CR20210486A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962822703P 2019-03-22 2019-03-22
US201962948697P 2019-12-16 2019-12-16
PCT/US2020/023819 WO2020197991A1 (en) 2019-03-22 2020-03-20 Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

Publications (1)

Publication Number Publication Date
CR20210486A true CR20210486A (es) 2021-12-07

Family

ID=70293100

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20210486A CR20210486A (es) 2019-03-22 2020-03-20 Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico
CR20240238A CR20240238A (es) 2019-03-22 2020-03-20 Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico (divisional 2021-0486)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20240238A CR20240238A (es) 2019-03-22 2020-03-20 Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico (divisional 2021-0486)

Country Status (28)

Country Link
US (4) US11084832B2 (es)
EP (2) EP3938047B1 (es)
JP (3) JP7265647B2 (es)
KR (2) KR102714084B1 (es)
CN (2) CN119462659A (es)
AU (3) AU2020245350B2 (es)
CL (2) CL2021002444A1 (es)
CO (1) CO2021012319A2 (es)
CR (2) CR20210486A (es)
DK (1) DK3938047T3 (es)
DO (2) DOP2021000195A (es)
ES (1) ES2927041T3 (es)
HR (1) HRP20221074T1 (es)
HU (1) HUE059677T2 (es)
IL (1) IL286328A (es)
LT (1) LT3938047T (es)
MX (2) MX2021011394A (es)
MY (1) MY201239A (es)
PE (1) PE20212074A1 (es)
PH (1) PH12021500040A1 (es)
PL (1) PL3938047T3 (es)
PT (1) PT3938047T (es)
SG (1) SG11202109650XA (es)
SI (1) SI3938047T1 (es)
TW (3) TWI745900B (es)
UA (1) UA127822C2 (es)
WO (1) WO2020197991A1 (es)
ZA (1) ZA202107015B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015013645A1 (en) 2013-07-25 2015-01-29 Convida Wireless, Llc End-to-end m2m service layer sessions
PE20251594A1 (es) 2018-05-31 2025-06-16 Shionogi & Co Derivado policiclico de carbamoilpiridona
AU2019277547B2 (en) 2018-05-31 2024-10-10 Shionogi & Co., Ltd. Polycyclic pyridone derivative
AU2019307500B2 (en) * 2018-07-16 2022-09-29 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
CN112753265B (zh) 2018-09-27 2025-02-11 交互数字专利控股公司 新无线电的未经许可的频谱中的子频带操作
CN119462659A (zh) 2019-03-22 2025-02-18 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其药学用途
US12577241B2 (en) 2019-11-28 2026-03-17 Shionogi & Co., Ltd. Polycyclic pyridopyrazine derivative
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
WO2022072520A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
CN114426540B (zh) * 2020-10-29 2024-04-26 上海拓界生物医药科技有限公司 吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用
TW202227445A (zh) * 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的ｈｉｖ病毒的用途
CN116745292A (zh) * 2021-01-19 2023-09-12 吉利德科学公司 经取代的吡啶并三嗪化合物及其用途
LT4196479T (lt) * 2021-01-19 2023-12-11 Gilead Sciences, Inc. Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
WO2023018913A1 (en) * 2021-08-11 2023-02-16 Merck Sharp & Dohme Llc Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza
WO2023081637A1 (en) * 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
EP4440700A1 (en) 2021-12-03 2024-10-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
HUE072195T2 (hu) 2021-12-03 2025-10-28 Gilead Sciences Inc Terápiás vegyületek HIV-vírusfertõzésre
JP7736929B2 (ja) 2021-12-03 2025-09-09 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
WO2023122781A2 (en) * 2021-12-23 2023-06-29 The Katholieke Universiteit Leuven Tetrahydrobenzoazepinones and related analogs for inhibiting yap/taz-tead
TW202446773A (zh) * 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TWI867601B (zh) 2022-07-01 2024-12-21 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
AU2024259111A1 (en) 2023-04-19 2025-10-16 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
WO2024249573A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Solid forms of compounds useful in the treatment of hiv
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於ｈｉｖ之治療性化合物
AU2023460182A1 (en) 2023-07-28 2026-02-05 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
AU2024357911A1 (en) * 2023-10-11 2026-03-26 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202530227A (zh) 2023-10-11 2025-08-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
TW202525289A (zh) * 2023-12-22 2025-07-01 美商基利科學股份有限公司 用於製備治療性化合物之方法及中間物
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4537885A (en) 1983-02-10 1985-08-27 Ciba Geigy Corporation Certain benzazocinone and benzazoninone derivatives
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
CN1291994C (zh) 2000-07-21 2006-12-27 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
DE602005027466D1 (de) 2004-07-27 2011-05-26 Gilead Sciences Inc Nukleosid phosphonat konjugate als anti hiv mittel
WO2006088173A1 (ja) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
AU2006228278C1 (en) * 2005-03-31 2011-06-23 Msd Italia S.R.L. HIV integrase inhibitors
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
JP2009503081A (ja) 2005-08-04 2009-01-29 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害薬
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
EP1950212B1 (en) 2005-10-27 2016-02-24 Shionogi Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
AU2006306355A1 (en) 2005-10-27 2007-05-03 Merck & Co., Inc. HIV integrase inhibitors
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CA2657287A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
AU2007313293A1 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. HIV integrase inhibitors
EP2170888B1 (en) 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2231621B1 (en) 2008-01-08 2016-11-02 Merck Sharp & Dohme Corp. Process for preparing n-substituted hydroxypyrimidinone carboxamides
US8129398B2 (en) * 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
CN104387382A (zh) 2008-03-24 2015-03-04 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
RS54008B1 (sr) 2008-04-23 2015-10-30 Gilead Sciences Inc. 1`-supstituisani karba-nukleozidni analozi za antivirusnu terapiju
WO2009154870A1 (en) 2008-05-05 2009-12-23 Merck & Co., Inc. Hiv integrase inhibitors
EP2247601B1 (en) 2008-07-02 2013-04-10 Avexa Limited Thiazopyrimidinones and uses thereof
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
US8217034B2 (en) 2008-07-25 2012-07-10 Shionogi & Co., Ltd. Chemical compounds
ES2395705T3 (es) 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
KR101695807B1 (ko) 2008-07-25 2017-01-13 비이브 헬쓰케어 컴퍼니 화합물
WO2010014913A1 (en) 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
CA2738814C (en) 2008-10-06 2014-01-28 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
DK2364314T3 (da) 2008-12-09 2014-05-12 Gilead Sciences Inc Modulatorer af toll-lignende receptorer
EP3210603A1 (en) 2008-12-11 2017-08-30 Shionogi & Co., Ltd Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
AU2010208470A1 (en) * 2009-01-28 2011-08-04 Merck Sharp & Dohme Corp. Bridged compounds as HIV integrase inhibitors
US8673307B1 (en) 2009-03-09 2014-03-18 The Rockefeller University HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2444400B1 (en) 2009-06-15 2018-03-28 Shionogi&Co., Ltd. Substituted polycyclic carbamoylpyridone derivative
WO2011011483A1 (en) 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
JP5756804B2 (ja) 2009-08-18 2015-07-29 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｏｌｌ様レセプターモジュレーターとしての置換ベンゾアゼピン
DK2467380T3 (en) 2009-08-18 2017-03-13 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS
WO2011025683A1 (en) 2009-08-26 2011-03-03 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
CA2777664C (en) 2009-10-13 2014-06-10 Johannes Wilhelmus J. Thuring Macrocyclic integrase inhibitors
ES2644286T3 (es) 2009-10-22 2017-11-28 Gilead Sciences, Inc. Derivados de purina o deazapurina útiles para el tratamiento de (entre otros) infecciones víricas
LT2932970T (lt) 2010-01-27 2018-06-25 Viiv Healthcare Company Antivirusinė terapija
KR20120130185A (ko) 2010-02-26 2012-11-29 니뽄 다바코 산교 가부시키가이샤 １,３,４,８―테트라히드로―２Ｈ―피리도［１,２―ａ］피라진 유도체 및 그의 ＨＩＶ 인테그라제 저해제로서의 이용
BR112012024796A2 (pt) 2010-04-02 2016-06-07 Janssen R&D Ireland inibidores de integrase macrocíclicos
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
AR082080A1 (es) 2010-07-02 2012-11-07 Gilead Sciences Inc Compuestos derivados de acido acetico-2-quinolinicos como compuestos antivirales anti hiv
TWI453208B (zh) 2010-07-02 2014-09-21 Gilead Sciences Inc 治療性化合物類
CR20170278A (es) 2010-07-22 2017-09-29 Gilead Sciences Inc Métodos y compuestos para tratar infecciones virales por paramyxoviridae
PL3456721T3 (pl) 2010-08-05 2021-10-25 Shionogi & Co., Ltd Sposób wytwarzania związków wykazujących działanie hamujące integrazę hiv
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
BR112013007678A2 (pt) 2010-10-01 2017-07-04 Ventirx Pharmaceuticals Inc método para tratamento de doenças alérgicas
EP3195868A3 (en) 2010-10-01 2017-08-02 VentiRx Pharmaceuticals, Inc. Therapeutic use of a tlr agonist and combination therapy
AU2011320651A1 (en) 2010-10-29 2013-05-02 Merck Canada Inc. HIV integrase inhibitors
US8835411B2 (en) * 2010-12-10 2014-09-16 Bristol-Myers Squibb Company HIV integrase inhibitors
CN106518851A (zh) 2011-01-12 2017-03-22 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
CN106749023A (zh) 2011-01-12 2017-05-31 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
SI3590928T1 (sl) 2011-04-08 2021-10-29 Janssen Sciences Ireland Unlimited Co Derivati pirimidina za zdravljenje virusnih okužb
PT2699558T (pt) 2011-04-21 2016-12-29 Gilead Sciences Inc Compostos de benzotiazole e a sua utilização farmacêutica
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
EA201990685A1 (ru) 2011-05-17 2019-12-30 Дзе Рокфеллер Юниверсити Нейтрализующие вирус иммунодефицита человека антитела и способы их применения
US8916575B2 (en) 2011-05-18 2014-12-23 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9493549B2 (en) 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
WO2013025788A1 (en) 2011-08-16 2013-02-21 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
WO2013086533A1 (en) 2011-12-08 2013-06-13 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
JP6144698B2 (ja) 2011-12-20 2017-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｉｖ複製の阻害剤としての縮合三環式化合物
TWI580668B (zh) 2011-12-21 2017-05-01 諾維拉治療公司 Ｂ型肝炎抗病毒劑
EP2812331B1 (en) 2012-02-08 2019-01-02 Janssen Sciences Ireland Unlimited Company Piperidino-pyrimidine derivatives for the treatment of viral infections
US20150044137A1 (en) 2012-03-23 2015-02-12 The United States of America, as represented by the Secretary, Dep. of Health Care Human Services Neutralizing antibodies to hiv-1 and their use
PT3070081T (pt) 2012-04-20 2018-05-21 Gilead Sciences Inc Derivados do ácido benzotiazol-6-ilacético e sua utilização para tratar uma infeção por vih
EP2865014A4 (en) 2012-06-25 2015-07-29 Sunpower Corp REINFORCEMENT FOR NETWORK OF SOLAR MODULES
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
WO2014014933A1 (en) 2012-07-20 2014-01-23 Merck Sharp & Dohme Corp. Hiv treatment with amido-substituted pyrimidinone derivatives
CN104781239B (zh) 2012-08-10 2019-03-01 爱尔兰詹森科学公司 用于治疗病毒感染和另外的疾病的烷基嘧啶衍生物
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
SI3333173T1 (sl) 2012-10-03 2019-08-30 Gilead Sciences, Inc. Postopki za pripravo analogov protivirusnega nukleotida
EP2906563B1 (en) 2012-10-10 2018-02-28 Janssen Sciences Ireland UC Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
SI2908912T1 (sl) 2012-10-18 2021-03-31 The Rockefeller University Široko nevtralizirajoča protitelesa proti HIV
DE102012220513B4 (de) 2012-11-12 2023-02-16 Bayerische Motoren Werke Aktiengesellschaft Verfahren und Vorrichtung zur Herstellung eines Druckgussteils
AU2013346793B2 (en) 2012-11-16 2018-03-08 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
EP2928924A4 (en) 2012-12-04 2016-07-13 Univ Maryland HIV-1 ENV BINDING ANTIBODIES, FUSION PROTEINS AND METHODS OF USE
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
PL3608325T3 (pl) * 2012-12-21 2022-11-07 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne
AU2013366981A1 (en) 2012-12-27 2015-06-18 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor
KR102300861B1 (ko) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
EP3330272B1 (en) 2013-05-17 2021-02-17 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2014200880A1 (en) * 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
NO2865735T3 (es) 2013-07-12 2018-07-21
HUE037347T2 (hu) 2013-07-12 2018-08-28 Gilead Sciences Inc Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
US20160244510A1 (en) 2013-09-27 2016-08-25 Duke University Human monoclonal antibodies
KR102102516B1 (ko) 2013-09-27 2020-04-20 머크 샤프 앤드 돔 코포레이션 Hiv 인테그라제 억제제로서 유용한 치환된 퀴놀리진 유도체
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US10421803B2 (en) 2014-01-31 2019-09-24 The Rockefeller University Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
NO2717902T3 (es) 2014-06-20 2018-06-23
US10676521B2 (en) 2014-07-21 2020-06-09 The Rockefeller University Combination of broadly neutralizing HIV antibodies and viral inducers
EP3757105B1 (en) 2014-08-22 2024-07-24 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
BR112017003663A2 (pt) 2014-08-27 2017-11-28 Viiv Healthcare Uk No 5 Ltd composto, composição, e, método para tratamento de infecção por hiv.
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
EP3229804B1 (en) * 2014-12-09 2020-05-06 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
ES2735087T3 (es) 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
EP3237397B1 (en) 2014-12-24 2018-11-21 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of hiv
US11071783B2 (en) 2015-03-19 2021-07-27 Duke University HIV-1 neutralizing antibodies and uses thereof
HRP20200583T1 (hr) 2015-03-20 2020-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protutijela koja neutraliziraju gp120 i njihova upotreba
WO2016154527A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
ES2837383T3 (es) * 2015-04-02 2021-06-30 Gilead Sciences Inc Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
WO2016179517A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
EP3377065B1 (en) 2015-11-17 2022-05-18 Merck Sharp & Dohme Corp. Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
CA3007022A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
WO2017096221A1 (en) 2015-12-02 2017-06-08 The Rockefeller University Bispecific anti-hiv broadly neutralizing antibodies
MA43389A (fr) 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
US20200079862A1 (en) 2015-12-03 2020-03-12 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
HUE056243T2 (hu) 2015-12-15 2022-02-28 Gilead Sciences Inc Emberi immunhiányt okozó vírust semlegesítõ ellenanyagok
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
CN107022027B (zh) 2016-02-02 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
CN107033241B (zh) 2016-02-03 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
US11117904B2 (en) 2016-06-23 2021-09-14 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
DK3347352T3 (da) 2016-08-19 2019-08-26 Gilead Sciences Inc Terapeutiske forbindelser anvendelige til profylaktisk eller terapeutisk behandling af en hiv-virusinfektion
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
EP3548031B1 (en) 2016-12-02 2023-07-19 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
US10786488B2 (en) 2017-01-26 2020-09-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
AR110922A1 (es) 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
CA3065328C (en) 2017-06-21 2023-08-15 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
EP3684767B1 (en) 2017-09-22 2024-04-24 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
WO2019087016A1 (en) 2017-10-30 2019-05-09 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
ES2992944T3 (en) 2018-02-13 2024-12-20 Cool Vapor Solutions Compositions for humidification and cooling of gas streams
EP3752144B1 (en) 2018-02-15 2022-12-28 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
JP2021522254A (ja) 2018-04-27 2021-08-30 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
AU2019277547B2 (en) 2018-05-31 2024-10-10 Shionogi & Co., Ltd. Polycyclic pyridone derivative
EP3802543A1 (en) 2018-05-31 2021-04-14 F. Hoffmann-La Roche AG Therapeutic compounds
PE20251594A1 (es) 2018-05-31 2025-06-16 Shionogi & Co Derivado policiclico de carbamoilpiridona
US11884683B2 (en) 2018-06-05 2024-01-30 Merck Sharp & Dohme Llc Tricyclic heterocycle compounds useful as HIV integrase inhibitors
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020004443A1 (ja) 2018-06-27 2020-01-02 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
KR102579246B1 (ko) 2018-07-03 2023-09-19 길리애드 사이언시즈, 인코포레이티드 HIV gp120을 표적화하는 항체 및 사용 방법
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
CA3115792A1 (en) 2018-10-10 2020-04-16 Janssen Biopharma, Inc. Macrocyclic flu endonuclease inhibitors
IL282551B2 (en) 2018-10-22 2025-11-01 Univ Nebraska Antiviral prodrugs and nanoformulations thereof
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
CN119462659A (zh) 2019-03-22 2025-02-18 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其药学用途
CN113795491B (zh) 2019-04-30 2024-09-03 上海拓界生物医药科技有限公司 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CN113226327B (zh) 2019-07-11 2022-05-17 南京征祥医药有限公司 可用于治疗流感病毒感染的化合物
WO2021093846A1 (zh) 2019-11-13 2021-05-20 上海拓界生物医药科技有限公司 新型四环杂环化合物及其药物用途
JPWO2021107066A1 (es) 2019-11-28 2021-06-03
US12577241B2 (en) 2019-11-28 2026-03-17 Shionogi & Co., Ltd. Polycyclic pyridopyrazine derivative
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
WO2022072520A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202227445A (zh) * 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的ｈｉｖ病毒的用途
LT4196479T (lt) 2021-01-19 2023-12-11 Gilead Sciences, Inc. Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
KR20230147131A (ko) 2021-02-16 2023-10-20 머크 샤프 앤드 돔 엘엘씨 Hiv 인테그라제 억제제로서 유용한 테트라시클릭 헤테로사이클 화합물
JP7467392B2 (ja) * 2021-07-07 2024-04-15 西日本電信電話株式会社 情報提供装置、作業者端末及びコンピュータープログラム
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Also Published As

Publication number Publication date
AU2023204700B2 (en) 2025-04-24
EP3938047B1 (en) 2022-06-22
KR20240151256A (ko) 2024-10-17
PE20212074A1 (es) 2021-10-26
SG11202109650XA (en) 2021-10-28
DOP2021000195A (es) 2021-10-31
ES2927041T3 (es) 2022-11-03
TWI745900B (zh) 2021-11-11
CN119462659A (zh) 2025-02-18
AU2025205458A1 (en) 2025-07-31
CA3128961A1 (en) 2020-10-01
US20230203061A1 (en) 2023-06-29
BR112021018827A2 (pt) 2021-11-23
PH12021500040A1 (en) 2022-06-06
MX2021011394A (es) 2021-10-13
JP2022526895A (ja) 2022-05-27
EP3938047A1 (en) 2022-01-19
NZ781550A (en) 2024-08-30
DK3938047T3 (da) 2022-09-05
HUE059677T2 (hu) 2022-12-28
MY201239A (en) 2024-02-13
KR20210142711A (ko) 2021-11-25
US20230027019A1 (en) 2023-01-26
AU2023204700A1 (en) 2023-08-10
AU2020245350A1 (en) 2021-11-18
TW202544011A (zh) 2025-11-16
AU2020245350B2 (en) 2023-04-20
SI3938047T1 (sl) 2022-10-28
PT3938047T (pt) 2022-10-03
LT3938047T (lt) 2022-10-10
US20200317689A1 (en) 2020-10-08
KR102714084B1 (ko) 2024-10-08
MX2024015459A (es) 2025-02-10
CO2021012319A2 (es) 2021-10-20
TW202102499A (zh) 2021-01-16
US11548902B1 (en) 2023-01-10
US11084832B2 (en) 2021-08-10
WO2020197991A1 (en) 2020-10-01
JP2025013503A (ja) 2025-01-24
CN113874079A (zh) 2021-12-31
US12227520B2 (en) 2025-02-18
TW202204356A (zh) 2022-02-01
JP7265647B2 (ja) 2023-04-26
EP4122537A1 (en) 2023-01-25
ZA202107015B (en) 2024-04-24
CL2021002444A1 (es) 2022-07-08
HRP20221074T1 (hr) 2022-11-11
TWI873387B (zh) 2025-02-21
DOP2022000240A (es) 2022-11-30
UA127822C2 (uk) 2024-01-10
JP7710476B2 (ja) 2025-07-18
PL3938047T3 (pl) 2022-11-07
CL2022003688A1 (es) 2023-07-28
JP2023033640A (ja) 2023-03-10
CR20240238A (es) 2024-08-12
IL286328A (en) 2021-10-31
US20250115619A1 (en) 2025-04-10
CN113874079B (zh) 2024-11-08

Similar Documents

Publication Publication Date Title
DOP2021000195A (es) Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
TR201905009T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
MX2022006940A (es) Composiciones farmaceuticas.
CY1119544T1 (el) Πολυκυκλικες ενωσεις καραβαμοϋλοπυριδονης και χρηση αυτων στη θεραπεια λοιμωξεων απο hiv
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2021012579A2 (es) Compuestos útiles en la terapia del vih
CR20210664A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
DOP2022000171A (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih
CO2019012035A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX384729B (es) Compuestos heterocíclicos tricíclicos útiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).
DOP2018000035A (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
UY37555A (es) Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
AR118477A1 (es) Compuestos tricíclicos puente de carbamoilpiridona y su uso farmacéutico
EA202192268A1 (ru) Мостиковые трициклические карбамоилпиридоновые соединения и их фармацевтическое применение